Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b
- 74 Downloads
We have evaluated the efficacy of interferon-α (IFN-α) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-α every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-α therapy (zinc sulfate group), and 15 patients took IFN-α and 150 mg of polaprezinc (polaprezinc group).
On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p<0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-α for chronic hepatitis C with genotype 1b.
Index EntriesChronic hepatitis C polaprezinc interferon-α HCV RNA
Unable to display preview. Download preview PDF.
- 25.T. Nagamine, H. Takagi, Y. Hashimoto, H. Takayama, R. Shimoda, N. Nomura, et al., The possible role of zinc and metallothionein in the liver on the therapeutic effect of interferon-αlpha to hepatitis C patients, Biol. Trace Element Res. 58, 65–76 (1997).Google Scholar
- 26.H. Sano, S. Furuta, S. Totama, M. Miwa, Y. Ikeda, M. Suzuki, et al., Study on the metabolic fate of catena-(S)-[μ[N a-(3-aminopropionyl) histidinate(2-)-N 1,N 2,O:N τ]-zinc], Drug Res. 41(II), 965–975 (1991).Google Scholar
- 27.A. Miyoshi, H. Matsuo, G. Miwa, and M. Nakajima, Clinical evaluation of Z-103 in the treatment of gastric ulcer, Jpn. Pharmacol. Ther. 20, 181–197 (1992).Google Scholar
- 28.T. Yoshikawa, Y. Naito, T. Tanigawa, T. Yoneta, and M. Kondo, The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinate zinc, Biochem. Biophys. Acta 115, 15–22 (1991).Google Scholar
- 29.H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, et al., Detection of hepatitis C virus RNA typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources, J. Gen. Virol. 73, 673–679 (1992).PubMedCrossRefGoogle Scholar
- 34.O. I. Arouma, M. J. Laughton, and B. Halliwell, Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo? Biochem. J. 264, 863–869 (1989).Google Scholar